

Anna Daunt

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/708507/anna-daunt-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

9

papers

324

citations

7

h-index

9

g-index

9

ext. papers

483

ext. citations

10.9

avg, IF

3.07

L-index

#	Paper	IF	Citations
9	Clinical Characteristics and Predictors of Outcomes of Hospitalized Patients With Coronavirus Disease 2019 in a Multiethnic London National Health Service Trust: A Retrospective Cohort Study. <i>Clinical Infectious Diseases</i> , 2021 , 73, e4047-e4057	11.6	52
8	SARS-CoV-2 lateral flow assays for possible use in national covid-19 seroprevalence surveys (React 2): diagnostic accuracy study. <i>BMJ, The</i> , 2021 , 372, n423	5.9	24
7	Prevalence of antibody positivity to SARS-CoV-2 following the first peak of infection in England: Serial cross-sectional studies of 365,000 adults. <i>Lancet Regional Health - Europe, The</i> , 2021 , 4, 100098		46
6	Factors associated with reattendance to emergency services following COVID-19 hospitalization. <i>Journal of Medical Virology</i> , 2021 , 93, 1250-1252	19.7	1
5	Validity of the UK early access to medicines scheme criteria for Remdesivir use in patients with COVID-19 disease. <i>Journal of Infection</i> , 2020 , 81, 647-679	18.9	1
4	In-hospital mortality is associated with inflammatory response in NAFLD patients admitted for COVID-19. <i>PLoS ONE</i> , 2020 , 15, e0240400	3.7	24
3	Clinical and laboratory evaluation of SARS-CoV-2 lateral flow assays for use in a national COVID-19 seroprevalence survey. <i>Thorax</i> , 2020 , 75, 1082-1088	7.3	85
2	Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults		67
1	REACT-2 Round 5: increasing prevalence of SARS-CoV-2 antibodies demonstrate impact of the second wave and of vaccine roll-out in England		24